Transneural Therapeutics Presents Preclinical Data on Lead Candidate TN-001 at 64th Annual Meeting of ACNP (2026)
PR Newswire —
Poster presentation highlighted promising pharmacology and behavioral results on lead candidate, TN-001, in preclinical studies. TN-001 is under development for both major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). TN-001 rapidly induces neuroplasticity,...